Based on combined treatment with agonistic anti-OX40 antibodies and anti-CTLA-4 antibodies, which induced tumor regression and improved survival[109], further early phase trials investigating combinations of OX40 and PD-L1 and OX40 and CTLA-4 are currently underway in advanced solid tumors (NCT02221960 & NCT02205333). The gene discussed is TNFRSF4; the disease is neoplasm.